Arrowhead Pharmaceuticals Toekomstige groei

Future criteriumcontroles 2/6

De verwachting is dat Arrowhead Pharmaceuticals de winst en omzet met respectievelijk 28.2% en 46.1% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 29.6% per jaar.

Belangrijke informatie

28.2%

Groei van de winst

29.6%

Groei van de winst per aandeel

Biotechs winstgroei	31.7%
Inkomstengroei	46.1%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Good
Laatst bijgewerkt	26 Nov 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Winst- en omzetgroeiprognoses

BOVESPA:A2RR34 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
9/30/2027	491	-327	-495	-161	6
9/30/2026	240	-459	-546	-408	12
9/30/2025	151	-497	-444	-389	16
9/30/2024	62	-535	-617	-479	16
6/30/2024	20	-539	-533	-352	N/A
3/31/2024	35	-471	-470	-257	N/A
12/31/2023	182	-297	-403	-196	N/A
9/30/2023	241	-205	-331	-154	N/A
6/30/2023	256	-181	-342	-197	N/A
3/31/2023	273	-150	-353	-245	N/A
12/31/2022	278	-155	-236	-150	N/A
9/30/2022	243	-176	-189	-136	N/A
6/30/2022	250	-154	-120	-91	N/A
3/31/2022	263	-112	-75	-52	N/A
12/31/2021	144	-183	124	149	N/A
9/30/2021	138	-141	148	171	N/A
6/30/2021	108	-126	167	184	N/A
3/31/2021	89	-110	165	181	N/A
12/31/2020	80	-103	-123	-111	N/A
9/30/2020	88	-85	-108	-96	N/A
6/30/2020	124	-24	-89	-71	N/A
3/31/2020	139	10	-46	-27	N/A
12/31/2019	164	53	-34	-19	N/A
9/30/2019	169	68	161	173	N/A
6/30/2019	137	46	152	157	N/A
3/31/2019	95	10	130	132	N/A
12/31/2018	47	-29	134	136	N/A
9/30/2018	16	-54	-49	-47	N/A
6/30/2018	14	-54	-55	-54	N/A
3/31/2018	22	-44	N/A	-50	N/A
12/31/2017	31	-35	N/A	-49	N/A
9/30/2017	31	-34	N/A	-24	N/A
6/30/2017	23	-46	N/A	-25	N/A
3/31/2017	13	-60	N/A	-33	N/A
12/31/2016	4	-75	N/A	-33	N/A
9/30/2016	0	-82	N/A	-64	N/A
6/30/2016	0	-84	N/A	-66	N/A
3/31/2016	0	-81	N/A	-61	N/A
12/31/2015	0	-89	N/A	-63	N/A
9/30/2015	0	-92	N/A	-66	N/A
6/30/2015	0	-90	N/A	-65	N/A
3/31/2015	0	-85	N/A	-61	N/A
12/31/2014	0	-71	N/A	-53	N/A
9/30/2014	0	-59	N/A	-35	N/A
6/30/2014	0	-50	N/A	-30	N/A
3/31/2014	0	-44	N/A	-25	N/A
12/31/2013	0	-37	N/A	-22	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat A2RR34 de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat A2RR34 de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat A2RR34 de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van A2RR34 ( 46.1% per jaar) zal naar verwachting sneller groeien dan de markt BR ( 7.4% per jaar).

Hoge groei-inkomsten: De omzet van A2RR34 ( 46.1% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van A2RR34 naar verwachting over 3 jaar hoog zal zijn

Arrowhead Pharmaceuticals Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Arrowhead Pharmaceuticals, Inc. Appoints Doug Ingram to the Board of Directors

Arrowhead Pharmaceuticals, Inc. Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals, Inc. Presents New Pivotal Phase 3 Data At ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals, Inc. to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, into Clinical Studies

Arrowhead Pharmaceuticals to Advance RNAi-Based Plozasiran into Phase 3 Capitan Cardiovascular Outcomes Trial

Arrowhead Pharmaceuticals, Inc. Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 Palisade Study in Patients with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease

Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 14, 2024

Arrowhead Pharmaceuticals, Inc. Announces Leaving of Javier San Martin, M.D., as the Chief Medical Officer, Effective from February 1, 2024

Arrowhead Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $450.015 million.

Arrowhead Pharmaceuticals, Inc. Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy

Arrowhead Pharmaceuticals Inc. Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate A Phase 1 Study of Aro-Sod1

Arrowhead Pharmaceuticals, Inc. Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-Mmp7 for Treatment of Idiopathic Pulmonary Fibrosis

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 16, 2023

Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR) acquired unknown majority stake in Visirna Therapeutics.

Arrowhead Pharmaceuticals Inc. and Takeda Pharmaceutical Company Limited Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Arrowhead Pharmaceuticals Inc. to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study

Arrowhead Presents New Phase 2 Data At AHA 2022 on Cardiometabolic Pipeline

Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data At AHA 2022 on SHASTA-2 Study of ARO-APOC3 and Arches-2 Study of ARO-ANG3

Arrowhead Pharmaceuticals, Inc. Appoints Patrick O’Brien as Chief Operating Officer

Arrowhead Pharmaceuticals Inc. Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE

Takeda and Arrowhead Announce Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine

Arrowhead Pharmaceuticals, Inc. Appoints Victoria Vakiener to Board of Directors

Arrowhead Pharmaceuticals Inc. Doses the First Patients in the Phase 2 GATEWAY Clinical Study of Investigational ARO-ANG3 for the Treatment of Patients with Homozygous Familial Hypercholesterolemia

Arrowhead Pharmaceuticals Inc. Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia

Arrowhead Pharmaceuticals, Inc. Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases

Arrowhead Pharmaceuticals, Inc. Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven